ClinicalTrials.gg

Program

olokizumab

Also written as “CDP6038”, “Olokizumab” and “OKZ q4w”.

Its studies are mostly in Arthritis, Rheumatoid · COVID-19 · Polymyalgia Rheumatica · Arthritis, Juvenile · Lung Diseases, Interstitial, led by 2 companies.

Furthest: phase 3, since Apr 29, 201619 company-led studies, 3 open or runningNext primary completion: Apr 9, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
R-Pharm113 open or runningphase 3since Apr 29, 2016Apr 29, 2016Apr 9, 2027phase 3 · NCT06440746
UCB80 open or runningphase 2since Nov 4, 2009Nov 4, 2009none ahead

Also a collaborator on its studies: keystat-llc, exacte-labs-llc, data-management-365, iqvia-pvt-ltd, quintiles-inc, k-research-llc, cromos-pharma-llc and covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 4, 2009.

  1. Jan 11, 2011Phase 1 study in PharmacokineticsUCB · NCT01276119 · 67 enrolled · Germany
  2. Feb 14, 2011Phase 2 study in Arthritis, RheumatoidUCB · NCT01296711 · 190 enrolled · United States, Belgium, United Kingdom
  3. Oct 27, 2011Phase 2 study in Arthritis, RheumatoidUCB · NCT01463059 · 119 enrolled · Japan, Korea, Republic of, Taiwan
  4. Feb 10, 2012Phase 2 study in Arthritis, RheumatoidUCB · NCT01533714 · 103 enrolled · Japan, Korea, Republic of, Taiwan
  5. Jul 3, 2012Phase 2 study in Crohn DiseaseUCB · NCT01635621
  6. Apr 29, 2016R-Pharm's first studies: 3 phase 3 studies in Arthritis, RheumatoidNew to R-PharmR-Pharm · NCT02760433, NCT02760407, NCT02760368
  7. Feb 7, 2017Phase 3 study in Arthritis, RheumatoidR-Pharm · NCT03120949 · 2,106 enrolled · United States, Argentina, Belarus and more
  8. Jan 27, 2020Phase 1 study in Arthritis, RheumatoidR-Pharm · NCT04246762 · 17 enrolled · Bulgaria, Moldova, Republic of
  9. May 6, 2020Phase 3 study in COVID-19R-Pharm · NCT04380519 · 372 enrolled · Russian Federation
  10. Jun 25, 2020Phase 3 study in COVID-19R-Pharm · NCT04452474
  11. Dec 24, 2021Phase 3 study in COVID-19R-Pharm · NCT05187793 · 198 enrolled · Russian Federation
  12. May 28, 2024Phase 3 study in Lung Diseases, InterstitialR-Pharm · NCT06440746 · 138 planned · Russian Federation
  13. Dec 30, 2025Phase 2 study in Arthritis, JuvenileR-Pharm · NCT07517575 · 71 planned · Russia
  14. Jun 19, 2026Phase 3 study in Polymyalgia RheumaticaR-Pharm · NCT07670546 · 125 enrolled · Russia

Ahead

  1. Apr 9, 2027Primary completion: phase 3 study in Lung Diseases, InterstitialR-Pharm · NCT06440746

TargetBeta

IL6 →read by rule
“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), ”NCIt, by rule
“Interleukin-6 inhibitor”ChEMBL 37, by rule

Other programs on IL6

ProgramCompanyFurthest phaseStudies
ziltivekimabruleNovo Nordiskphase 312
clazakizumabCSLphase 310
pacibekitugruleNovartisphase 31
isomyosamineruletnf-pharmaceuticals-incphase 21

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07670546Polymyalgia Rheumatica · Russia3Active, not recruitingR-PharmApr 10, 2026125
NCT07517575Arthritis, Juvenile · Russia2RecruitingR-PharmSep 202671
NCT06440746Lung Diseases, Interstitial · Russian Federation3RecruitingR-PharmApr 9, 2027138
NCT05187793COVID-19 · Russian Federation3UNKNOWNR-PharmOct 31, 2022198
NCT04452474COVID-193WithdrawnR-PharmNov 16, 20200
NCT04380519COVID-19 · Russian Federation3CompletedR-PharmJul 10, 2020372
NCT04246762Arthritis, Rheumatoid · Bulgaria, Moldova, Republic of1CompletedR-PharmJun 8, 202217
NCT03120949Arthritis, Rheumatoid · United States, Argentina, Belarus and more3CompletedR-PharmSep 1, 20212,106
NCT02760433Arthritis, Rheumatoid · United States, Argentina, Brazil and more3CompletedR-PharmSep 12, 2019368
NCT02760407Arthritis, Rheumatoid · United States, Argentina, Brazil and more3CompletedR-PharmAug 2, 20191,648
NCT02760368Arthritis, Rheumatoid · Belarus, Bulgaria, Russian Federation3CompletedR-PharmAug 2018428
NCT01635621Crohn Disease2WithdrawnUCBAug 20130
NCT01533714Arthritis, Rheumatoid · Japan, Korea, Republic of, Taiwan2TerminatedUCBNov 27, 2013103
NCT01463059Arthritis, Rheumatoid · Japan, Korea, Republic of, Taiwan2CompletedUCBFeb 2013119
NCT01296711Arthritis, Rheumatoid · United States, Belgium, United Kingdom2TerminatedUCBMay 1, 2013190
NCT01276119Pharmacokinetics · Germany1CompletedUCBOct 200967
NCT01262794Healthy Volunteers · United Kingdom1CompletedUCBSep 201120
NCT01242488Arthritis, Rheumatoid · United States, Belgium, United Kingdom2CompletedUCBJun 2012221
NCT01009242Arthritis · United States, Germany2CompletedUCBSep 201040

How it is read

Names in the registry

  • “CDP6038”, 13 entries
  • “Olokizumab”, 5 entries
  • “OKZ q4w”, 2 entries
  • “CDP6038 (olokizumab)”, 2 entries
  • “Olokizumab 64 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.